rosiglitazone has been researched along with 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gege, C; Hoffmann, T; Schlüter, T | 1 |
| Berenz, A; Haugen, BR; Hays, WR; Klopper, JP; Loi, M; Pugazhenthi, U; Said, S; Sharma, V | 1 |
2 other study(ies) available for rosiglitazone and 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid
| Article | Year |
|---|---|
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Topics: Benzeneacetamides; Drug Inverse Agonism; Fluorescence Resonance Energy Transfer; Humans; Ligands; Nuclear Receptor Subfamily 1, Group F, Member 2; Nuclear Receptor Subfamily 1, Group F, Member 3; Protein Binding; Th17 Cells; Thiazoles; Tretinoin | 2014 |
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Ligands; Melanoma; Mice; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Retinoids; RNA, Small Interfering; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2009 |